STAGE IVA PROSTATE CANCER AJCC V8
Clinical trials for STAGE IVA PROSTATE CANCER AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE IVA PROSTATE CANCER AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE IVA PROSTATE CANCER AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Prostate cancer breakthrough: pausing treatment may restore testosterone
Disease control OngoingThis study looks at whether men whose metastatic prostate cancer has responded very well to hormone therapy can safely take a break from treatment. The goal is to see if pausing therapy allows their testosterone levels to return to normal while keeping the cancer under control. A…
Matched conditions: STAGE IVA PROSTATE CANCER AJCC V8
Phase: PHASE2 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated May 01, 2026 15:43 UTC
-
New combo therapy targets hard-to-treat cancers in early trial
Disease control OngoingThis early-phase study tests a new drug (DS3201) combined with an immunotherapy (ipilimumab) in 65 people with advanced prostate, bladder, or kidney cancer that has spread. The main goals are to find the safest dose and check side effects. Researchers hope this combination can he…
Matched conditions: STAGE IVA PROSTATE CANCER AJCC V8
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 01, 2026 15:43 UTC
-
New drug combo aims to control spread of prostate cancer
Disease control OngoingThis study tests a three-drug combination (abiraterone, prednisone, and apalutamide) in 60 men with prostate cancer that has spread but hasn't yet been treated with hormone therapy. The goal is to see how long the treatment can control the cancer. Participants must have high-risk…
Matched conditions: STAGE IVA PROSTATE CANCER AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 29, 2026 15:05 UTC